{
    "id": 428,
    "fullName": "AKT2 wild-type",
    "impact": "none",
    "proteinEffect": "no effect",
    "geneVariantDescriptions": [
        {
            "description": "Wild-type AKT2 indicates that no mutation has been detected within the AKT2 gene.",
            "references": [
                {
                    "id": 275,
                    "pubMedId": null,
                    "title": "External Reference Not Available (N/A)",
                    "url": "https://ckb.jax.org/about/glossaryOfTerms"
                }
            ]
        }
    ],
    "type": "non-specific",
    "gene": {
        "id": 208,
        "geneSymbol": "AKT2",
        "terms": [
            "AKT2",
            "HIHGHH",
            "PKBB",
            "PKBBETA",
            "PRKBB",
            "RAC-BETA"
        ]
    },
    "variant": "wild-type",
    "createDate": "04/28/2014",
    "updateDate": "08/23/2018",
    "referenceTranscriptCoordinates": null,
    "partnerGenes": [
        
    ],
    "evidence": [
        {
            "id": 1222,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, GSK2141795 inhibited all isoforms of AKT in human cancer cell lines (PMID: 23795919).",
            "molecularProfile": {
                "id": 506,
                "profileName": "AKT2 wild-type"
            },
            "therapy": {
                "id": 764,
                "therapyName": "Uprosertib",
                "synonyms": null
            },
            "indication": {
                "id": 162,
                "name": "cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 184,
                    "pubMedId": 23795919,
                    "title": "Characterization of a chemical affinity probe targeting Akt kinases.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/23795919"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 999,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In preclinical studies, CCT128930 blocked AKT activity as evidenced inhibition of substrate phosphorylation and induction of cell cycle arrest in a variety of cancer cell lines (PMID: 21191045).",
            "molecularProfile": {
                "id": 506,
                "profileName": "AKT2 wild-type"
            },
            "therapy": {
                "id": 1445,
                "therapyName": "CCT128930",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 692,
                    "pubMedId": 21191045,
                    "title": "Preclinical pharmacology, antitumor activity, and development of pharmacodynamic markers for the novel, potent AKT inhibitor CCT128930.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/21191045"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        }
    ],
    "molecularProfiles": [
        {
            "id": 506,
            "profileName": "AKT2 wild-type",
            "profileTreatmentApproaches": [
                {
                    "id": 108,
                    "name": "Akt2 Inhibitor",
                    "profileName": "AKT2 wild-type"
                }
            ]
        }
    ],
    "allTranscriptCoordinates": [
        
    ]
}